A Randomized, Parallel-group, Open-Label, Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis.
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Abbott Laboratories
- 23 Jun 2016 Results of safety analysis of this and other trials published in the Annals of the Rheumatic Diseases.
- 15 Apr 2008 New trial record.